Quidel Q1 2022: Rapid Immunoassay Demand Props Up QDEL as Cardiometabolic Transitions Weigh on the Ledger

Ticker: QDEL • EPS figures ahead and behind expectations are a frequent plot in these quarterly acts; EPS consensus and revenue forecast chatter often outpace the press release itself. Here’s a close look at Quidel Corporation’s first-quarter 2022 results and what they might portend for peers in the diagnostic space.

Executive snapshot: big top-line, remarkable EPS, and product mix swing

Quidel Corporation, NASDAQ: QDEL, reported a first-quarter 2022 revenue of about $1,002.3 million, marking a 167% year-over-year surge from the prior-year quarter. The company delivered GAAP EPS of $11.31 per diluted share and non-GAAP EPS of $11.66 per diluted share, highlighting a windfall of high-demand Rapid Immunoassay products. The gloss on the headline numbers is real: the rapid testing cycle is still front and center, even as the company navigates a transitional period in its disease-panel portfolio.

Management framed the quarter as a tale of product category strength driven largely by at-home and point-of-care tests, with currencies and portfolio mix shaping the bottom line. The press release emphasizes a 167% revenue rise and a substantial lift in Rapid Immunoassay revenue, while noting a meaningful contribution from Beckman Coulter’s transition affecting Cardiometabolic Immunoassay revenue.

Where the dollars came from: rapid tests, influenza, and the Beckman transition

Rapid Immunoassay revenues surged to approximately $892.8 million, boosted by strong demand for QuickVue at-home tests and related SARS-CoV-2 testing solutions. The company also pointed to influenza-related testing as a contributor to the mix, with Influenza product sales totaling about $89.1 million in the quarter. The momentum in rapid diagnostics is the narrative, but the portfolio math is nuanced.

Beckman Coulter’s transition impact is a notable line item: Cardiometabolic Immunoassay revenue totaled $50.2 million in Q1 2022, down from $66.6 million in Q1 2021. The company attributes part of this shift to the transition agreement, under which $16.8 million in revenue in Q1 2022 replaced what would have otherwise appeared in the Cardiometabolic line (versus $33.5 million in Q1 2021). In other words, this quarter’s top-line strength rests on rapid tests, while a portion of the traditional cardiometabolic business moved to a partner arrangement.

Molecular Diagnostic Solutions posted about $46.0 million in revenue for the quarter, underscoring the ongoing reallocation within Quidel’s diagnostic stack as it pivots toward testing solutions with higher near-term demand.

Headwinds and tailwinds: currency and the transition effect

Analysts should note that currency exchange had an unfavorable impact of about $1.0 million on the quarter, a reminder that even in a period of outsized product demand, foreign exchange remains a quiet, persistent factor. The quarter’s results reflect a company navigating a tumultuous mix: explosive demand for rapid antigen tests, a partial reallocation of revenues from Beckman Coulter’s transition, and the ongoing timing and composition of its broader diagnostic offerings.

Outlook for the quarter and the industry: what to watch

The exhibit does not present forward-looking revenue guidance or an explicit EPS forecast in the excerpt, leaving EPS consensus and revenue forecast discussions implicit rather than explicit. For investors and peers, the key questions are whether the rapid-immunoassay advantage persists as COVID testing volumes normalize, and whether the Cardiometabolic corridor can stabilize as Beckman Coulter’s transition completes.

In the sector, the story is less about one quarter’s numbers and more about the durability of demand for at-home and rapid diagnostics, the pace of portfolio realignment, and how much of the COVID-era tailwind becomes a sustainable runway. The company’s results imply a two-speed dynamic: robust growth in rapid tests, offset by transitional headwinds in non-rapid segments.

Investment take: what this portends for QDEL and peers

First, the magnitude of the EPS figures versus the prior year underscores a business model that can scale when demand for rapid testing is high. The GAAP and non-GAAP EPS prints, paired with a $1 billion-plus revenue quarter, suggest the margin structure is being buoyed by product mix—rapid tests tend to carry favorable unit economics in the near term, especially when volumes spike.

Second, the Beckman Coulter transition is a reminder that portfolio transitions, not just demand surges, drive earnings dispersion. If the transition demand persists longer than expected, or if the residual customer migration accelerates, the company could see a more pronounced shift in the segment mix over the next few quarters. Investors should watch for cadence updates on the transition’s revenue recognition and any related margin effects.

Third, the balance of COVID-19 product demand against Cardiometabolic and Molecular Diagnostics suggests sector peers should monitor similarly tilted product portfolios. A few questions to consider: will at-home rapid tests remain a meaningful revenue stream as the pandemic phase evolves? How quickly will the non-rapid segments recover or stabilize? And what does that imply for EPS sustainability—both GAAP and non-GAAP—in a world where tests are a utility rather than a novelty?

Context from the company’s communication

The press materials note primary contact points for media and investor inquiries and reaffirm the company’s cadence around quarterly disclosures. As with many earnings releases, the underlying narrative is as much about the story a company tells as the numbers themselves—the narrative here centers on rapid diagnostics’ continued relevance and the ongoing portfolio transition.

What this means for sector peers

Rapid diagnostic leaders may enjoy continued revenue visibility in periods of elevated testing demand, but must manage the risk of demand normalization.
Portfolio restructuring, like Beckman Coulter’s transition, can create near-term volatility but may yield longer-term efficiency gains if executed well.
Currency dynamics and product mix remain persistent considerations for reported EPS and margin trajectories across the diagnostic space.

Conclusion: a quarter that tests the balance of speed and scope

Quidel’s first quarter of 2022 reinforces a simple arithmetic truth: when a company dominates a brisk segment, a single line item—rapid immunoassay revenue—can do a lot of the heavy lifting. The EPS figures reflect not just higher volumes, but a shift in the business’s core mix. For investors, the question is not only how much the quarter beat or missed a pure number, but how durable the rapid-test tailwinds are and how quickly the non-rapid portfolio settles into a sustainable rhythm. In the near term, the stock will likely ride the tide of demand for quick diagnostic results; in the medium term, it will have to prove that the transitional pieces of its business model can stand without the COVID-era stimulus.

Quidel Corporation (NASDAQ: QDEL) remains a name to watch in the broader diagnostics arena as the sector reconciles pandemic-era demand with a post-pandemic market reality. If earnings surprises re-emerge—whether on GAAP or non-GAAP metrics—and if the revenue forecast for the non-rapid segments comes into clearer view, incumbents and challengers alike will be priced for a sector still in motion, not in stasis.